Snapshot img

Cancer Registry Software Market Size 2025-2029

The cancer registry software market size is forecast to increase by USD 121.9 million, at a CAGR of 14% between 2024 and 2029.

The market is witnessing significant growth due to the escalating prevalence of cancer cases worldwide. The increasing incidence of various types of cancer necessitates the implementation of advanced registry software solutions to manage and analyze patient data more efficiently. Moreover, the burgeoning clinical research in oncology further drives the demand for these systems, as they facilitate data collection, management, and analysis for research purposes. However, the market faces challenges in the form of stringent data privacy and security concerns. With the growing amount of sensitive patient information being stored and shared digitally, ensuring robust data security becomes crucial. The potential risks of data breaches and unauthorized access can significantly impact both patients and healthcare providers, necessitating the adoption of advanced security measures. Companies in the market must prioritize data security and privacy to gain the trust of healthcare organizations and patients alike.

What will be the Size of the Cancer Registry Software Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free SampleThe market is a dynamic and evolving landscape, continually adapting to advancements in healthcare technology and the growing demand for comprehensive cancer data management. This market encompasses various applications, including disease registry management, cancer staging system, data warehousing, cancer incidence tracking, registry software architecture, data integration platform, clinical data capture, case reporting system, statistical reporting, cancer screening programs, and more. These tools play a crucial role in cancer surveillance systems, enabling the collection, analysis, and reporting of epidemiological data for public health surveillance. They facilitate data encryption for patient data privacy, ensuring HIPAA compliance. Data interoperability and data quality metrics are essential components, allowing for seamless integration of various health informatics tools. Real-time data updates and database management systems are integral to maintaining accurate and up-to-date information. Predictive modeling tools and data mining techniques contribute to risk factor identification and mortality data analysis. Data visualization tools offer valuable insights into the complexities of cancer data. Cancer registry software architecture supports population-based registry initiatives, ensuring secure data storage and registry reporting features. Oncology data management tools enable clinical data capture, case reporting, and statistical reporting, enhancing overall patient care. The ongoing development and refinement of these tools reflect the continuous unfolding of market activities and evolving patterns in cancer data management.

How is this Cancer Registry Software Industry segmented?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. End-userGovernment and third partyPharma biotech and medical device companiesHospitals and medical practicePrivate payersResearch institutesTypeStand-alone softwareIntegrated softwareDeploymentOn-premisesCloud-basedGeographyNorth AmericaUSCanadaMexicoEuropeFranceGermanyItalySpainUKAPACChinaJapanRest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period.Cancer registry software solutions play a vital role in assisting government and third-party agencies in managing and analyzing data related to cancer cases. These systems enable the tracking of cancer incidence, prevalence, and mortality rates, providing essential information for public health planning, resource allocation, and policy development. Analyzing trends and patterns in registry data helps identify high-risk populations, geographic disparities, and emerging cancer types. Governments utilize cancer registry software to monitor and improve the quality of cancer care. By evaluating variations in treatment practices and adherence to clinical guidelines, they can benchmark outcomes against national or international standards. Additionally, these software solutions facilitate data interoperability, ensuring data quality metrics and HIPAA compliance. Data encryption, data visualization tools, and predictive modeling capabilities enhance the functionality of cancer registry software. Epidemiological data analysis and risk factor identificatio

Oncology Information System (OIS) Market Outlook

The global Oncology Information System (OIS) market size is projected to reach approximately USD 4.5 billion by 2032, up from USD 2.0 billion in 2023, growing at a compound annual growth rate (CAGR) of 9.3% during the forecast period. The growth of the OIS market is primarily driven by the increasing incidence of cancer worldwide, coupled with the growing adoption of advanced healthcare information technologies. The need for efficient management of oncology patient data and the desire to enhance treatment outcomes are significant factors fueling market expansion. Additionally, the continuous advancements in health IT and the integration of artificial intelligence in oncology care are anticipated to offer a robust momentum to the market's growth trajectory.

The rising burden of cancer globally is a significant growth driver for the OIS market. According to various health organizations, cancer incidence has been steadily increasing, necessitating sophisticated systems to manage complex care processes. Oncology Information Systems play a crucial role in streamlining patient data management, improving workflow efficiency, and supporting clinical decision-making. These benefits are driving their adoption in hospitals and specialty clinics around the world. Moreover, the increasing availability of healthcare IT infrastructure, particularly in emerging economies, is further augmenting the demand for OIS solutions. Healthcare institutions are increasingly recognizing the value of digital solutions in improving patient care and operational efficiency, thus contributing to the market's growth.

Technological advancements in healthcare and the integration of artificial intelligence and machine learning technologies into OIS are also pivotal growth factors. These technologies enhance the capabilities of OIS by providing predictive analytics, personalized treatment plans, and improved patient monitoring. As cancer treatment becomes more personalized and complex, the use of AI-driven insights in OIS can significantly enhance treatment precision and outcomes. This integration not only aids healthcare professionals in making informed decisions but also facilitates a more patient-centric approach, thereby improving the overall quality of care. The ongoing research and development activities focused on introducing innovative features in OIS are expected to further drive market growth.

Another crucial factor contributing to the market expansion is the government initiatives aimed at improving cancer care infrastructure. Many countries are investing in healthcare IT systems to improve the quality of cancer care services. These government-sponsored programs are encouraging the adoption of OIS systems across healthcare facilities, thereby facilitating market growth. Additionally, the trend towards value-based care and reimbursement policies that encourage the use of technology in improving patient outcomes are further supporting the market's expansion. As healthcare systems globally are under pressure to reduce costs while improving care quality, the adoption of comprehensive OIS solutions becomes increasingly attractive.

Product Type Analysis

The OIS market is segmented by product type into software and services. Software solutions form a significant part of the market, driven by the need for efficient and comprehensive data management tools in cancer care. These software solutions include electronic health records, treatment and planning systems, and data analytics tools, which are critical for the effective management of oncology practices. The demand for robust software solutions is pushed by the increasing complexity of cancer treatments and the need for personalized care, which requires advanced software capabilities for data integration and analysis. The continuous evolution of software solutions with enhanced functionalities and user-friendly interfaces contributes to their growing adoption.

On the other hand, services associated with OIS, including installation, training, and maintenance, are pivotal for the seamless integration and functioning of these systems. As the demand for OIS solutions grows, so does the need for professional services to ensure their effective deployment and operation. Service providers are increasingly focusing on offering comprehensive support packages that enhance user experience and system efficiency. With the proliferation of cloud-based solutions, the demand for managed services is also anticipated to rise, as healthcare providers seek to outsource IT management to focus on core clinical activities. This trend is likely to cr

The Cancer in Young People in Canada (CYP-C) Data Tool provides pan-Canadian surveillance data on children and youth with cancer to inform research and planning for cancer control efforts. The CYP-C surveillance system operates through a collaboration between the Public Health Agency of Canada, the Canadian Partnership Against Cancer, and the C17 Council, a network of all seventeen children’s cancer hospitals across the country.

Cancer Registry Software Market Outlook

According to our latest research, the global cancer registry software market size reached a value of USD 97.2 million in 2024, reflecting the increasing adoption of digital health solutions across healthcare systems worldwide. The market is projected to expand at a robust CAGR of 11.4% during the forecast period, reaching USD 266.1 million by 2033. This growth is primarily driven by the rising incidence of cancer globally, the urgent need for comprehensive data management, and the growing emphasis on population health management and cancer surveillance.

A significant growth factor for the cancer registry software market is the mounting burden of cancer cases worldwide. With cancer remaining one of the leading causes of morbidity and mortality, healthcare providers and policymakers are increasingly prioritizing the collection, analysis, and utilization of cancer data. Cancer registry software enables efficient and accurate data collection, which is essential for tracking cancer incidence, planning resource allocation, and monitoring the effectiveness of public health interventions. The integration of advanced analytics and artificial intelligence capabilities into these platforms further enhances their value, allowing for deeper insights and more effective decision-making in cancer care.

Another key driver is the shift toward value-based healthcare and the growing importance of data-driven decision-making in clinical settings. Cancer registry software facilitates standardized data entry, interoperability with electronic health records (EHRs), and streamlined reporting to national and regional cancer registries. These features not only improve data quality and completeness but also support compliance with regulatory requirements and accreditation standards. As healthcare systems worldwide move towards digital transformation, the demand for robust, scalable, and user-friendly cancer registry software is expected to rise, fueling market growth.

The increasing focus on research and clinical trials is also propelling the adoption of cancer registry software. Pharmaceutical companies, research institutions, and government organizations rely on accurate and comprehensive cancer data to design, implement, and evaluate clinical studies. Cancer registry software enables efficient patient identification, longitudinal tracking, and outcome measurement, all of which are critical for advancing cancer research and developing new therapies. Furthermore, the growing trend toward personalized medicine and precision oncology underscores the need for sophisticated data management tools that can handle complex datasets and support advanced analytics.

From a regional perspective, North America currently dominates the cancer registry software market, driven by a well-established healthcare infrastructure, high adoption rates of health IT solutions, and robust government initiatives aimed at cancer surveillance and research. Europe follows closely, benefiting from strong regulatory frameworks and increasing investments in healthcare digitization. The Asia Pacific region is emerging as a high-growth market, fueled by rising cancer incidence, expanding healthcare infrastructure, and increasing awareness about the benefits of cancer registry software. Countries such as China, India, and Japan are witnessing substantial investments in healthcare IT, which is expected to drive market expansion in the coming years.

Type Analysis

The cancer registry software market is segmented by type into standalone software and integrated software, each catering to distinct user needs and operational requirements. Standalone software solutions are designed to function independently, offering dedicated features for cancer data collection, management, and reporting. These solutions are particularly favored by smaller healthcare facilities and research centers that require a focused, cost-effective approach to cancer registry management. Standalone systems are often easier to implement and maintain, making them an attractive option for organiz

The Oncology Informatics market is experiencing robust growth, driven by the increasing prevalence of cancer globally, advancements in data analytics and artificial intelligence (AI), and the rising adoption of electronic health records (EHRs) in oncology practices. The market's expansion is fueled by the need for improved cancer diagnosis, treatment planning, and patient monitoring, leading to more efficient and effective healthcare delivery. Key application areas include breast, prostate, colorectal, and cervical cancer, with a significant contribution from other cancer types as well. The integration of various informatics solutions, including EHRs, Population Health Management (PHM) systems, and Clinical Decision Support Systems (CDSS), is streamlining workflows and improving clinical outcomes. Furthermore, the burgeoning field of drug discovery and development informatics is leveraging data-driven insights to accelerate the development of novel cancer therapies. This market is expected to witness a considerable increase in the coming years with substantial market expansion in North America and Europe. Though factors such as high implementation costs and data security concerns can hinder widespread adoption, the overall market trajectory points towards substantial growth. The competitive landscape is characterized by a mix of established players like Cerner Corporation, IBM Corporation, and McKesson Corporation, alongside specialized oncology informatics companies like Inspirata Inc. and Oncology Analytics, Inc. These companies are constantly innovating to offer advanced analytics, predictive modeling, and personalized medicine solutions. The market is segmented by application (cancer type) and type of informatics solution, reflecting the diverse needs of oncology practices and research institutions. The continued development of AI-powered tools for image analysis, genomic data interpretation, and clinical trial management will further propel market growth. Regional variations exist, with North America and Europe currently dominating the market due to advanced healthcare infrastructure and higher adoption rates. However, Asia-Pacific is expected to witness significant growth in the coming years, driven by rising healthcare expenditure and increased cancer incidence. A conservative estimate suggests a steady growth trajectory, reflecting a balance between market drivers and potential restraints.

Cancer Registry Data Management Software Market Outlook

The Cancer Registry Data Management Software Market is poised for significant growth over the coming years, with the market size expected to increase from USD 250 million in 2023 to approximately USD 480 million by 2032, reflecting a compound annual growth rate (CAGR) of 7.5%. This growth is largely driven by the increasing need for comprehensive data management solutions in the healthcare sector, particularly in managing and analyzing cancer-related data. The rising incidence of cancer worldwide necessitates efficient data management systems, prompting healthcare providers to adopt advanced software solutions that facilitate better patient outcomes and streamlined data handling processes.

One of the primary growth factors for this market is the escalating prevalence of cancer globally, which is driving the demand for robust data management systems. As cancer cases continue to rise, healthcare institutions are in urgent need of sophisticated software solutions that can handle large volumes of data, aid in the tracking and monitoring of patient information, and enhance collaborative research efforts. This has led to increased investments in cancer registry software, as these tools are essential for effective cancer surveillance and control strategies. Furthermore, government initiatives focused on cancer prevention and management are also propelling the demand for such data management solutions, as they provide crucial support in policy formulation and healthcare planning.

Another critical factor contributing to the market's growth is the technological advancements in data management software, which have made these solutions more efficient, user-friendly, and capable of integrating with other healthcare systems. Innovations in artificial intelligence and machine learning have further enhanced the analytical capabilities of cancer registry software, enabling healthcare providers to gain deeper insights into cancer trends and patient outcomes. Additionally, the shift towards cloud-based solutions provides users with greater flexibility and scalability, allowing healthcare organizations to manage their data more effectively and securely across different locations.

The rising importance of personalized medicine and precision oncology is also driving the growth of the cancer registry data management software market. As the focus on targeted therapies and individualized treatment plans intensifies, there is an increasing reliance on comprehensive data management systems that can collate and analyze genetic, clinical, and treatment data. These systems are crucial for understanding patient responses to specific therapies and for driving research in personalized cancer treatments. Consequently, there is a growing demand for software that can support such complex data requirements, thereby fueling market expansion.

Regionally, North America holds a significant share in the cancer registry data management software market due to the presence of advanced healthcare infrastructure, high healthcare expenditure, and proactive government policies aimed at cancer management. The region's well-established healthcare system and emphasis on research and development create a conducive environment for the adoption of cutting-edge data management solutions. Additionally, Europe is also expected to witness substantial growth, driven by increasing awareness about cancer care and the implementation of health information technology. Meanwhile, the Asia Pacific region is anticipated to emerge as a high-growth market owing to the rising prevalence of cancer, expanding healthcare infrastructure, and increased healthcare spending in countries such as China and India.

Component Analysis

The cancer registry data management software market is segmented by components into software and services. Software solutions form the backbone of this market, as they provide the essential functionalities needed for data entry, storage, retrieval, and analysis. These software solutions are designed to streamline the workflow of cancer registries, improve data accuracy, and enhance data security. As the backbone of cancer data management, these software solutions are continually being upgraded to incorporate the latest advancements in technology, such as cloud computing and artificial intelligence. This continuous innovation is essential in handling the increasing volume and complexity of cancer data.

On the services side, there is a growing demand for support and maintenance services, which are crucial for ensuring the smooth operation of cancer reg

Oncology Informatics Market Outlook

The global oncology informatics market size was valued at approximately USD 7.5 billion in 2023 and is anticipated to reach around USD 19.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.1% during the forecast period. This remarkable growth can be attributed to the increasing prevalence of cancer, the rising need for personalized medicine, and the integration of advanced technologies like AI and machine learning in healthcare.

One of the primary growth factors driving the oncology informatics market is the rising incidence of cancer worldwide. According to the World Health Organization (WHO), there were an estimated 19.3 million new cancer cases globally in 2020. This alarming figure is expected to rise, propelling the demand for enhanced data management and analytical solutions to improve patient outcomes. Oncology informatics provides healthcare providers with the tools necessary to manage and analyze vast amounts of data, enabling more precise diagnosis and treatment planning.

Another significant growth factor is the increasing adoption of personalized medicine. Personalized medicine involves tailoring medical treatment to the individual characteristics of each patient, which requires detailed and accurate data on genetic, environmental, and lifestyle factors. Oncology informatics facilitates the collection, storage, and analysis of this data, helping clinicians to develop more effective and personalized treatment plans. This trend is expected to drive substantial investments in oncology informatics solutions, further boosting market growth.

The integration of advanced technologies such as artificial intelligence (AI) and machine learning (ML) into oncology informatics systems is also a key driver of market growth. These technologies enable the automated analysis of large datasets, identification of patterns, and prediction of patient outcomes, thereby enhancing the accuracy and efficiency of cancer diagnosis and treatment. The continuous advancements in AI and ML are expected to lead to the development of more sophisticated oncology informatics solutions, providing significant growth opportunities for market players.

Regionally, North America holds a dominant position in the oncology informatics market, driven by the high prevalence of cancer, substantial healthcare expenditure, and the presence of major industry players. Europe follows closely, with a strong focus on research and development and favorable government initiatives promoting the adoption of advanced healthcare technologies. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, attributed to the increasing healthcare spending, improving healthcare infrastructure, and growing awareness about the benefits of oncology informatics.

Component Analysis

The oncology informatics market is segmented by component into software and services. The software segment encompasses various solutions such as electronic health records (EHRs), picture archiving and communication systems (PACS), and oncology-specific software that assist in data management, analysis, and visualization. The services segment includes consulting, implementation, training, and maintenance services that support the deployment and use of oncology informatics solutions.

The software segment is expected to dominate the market throughout the forecast period, driven by the increasing adoption of EHRs and other advanced software tools in healthcare facilities. These software solutions enable efficient data management, streamlined workflows, and improved patient care, which are crucial in the treatment of complex diseases like cancer. Furthermore, continuous advancements in software technologies, including the incorporation of AI and ML, are anticipated to enhance the capabilities of oncology informatics software, driving further growth in this segment.

The services segment is also poised for significant growth, as healthcare providers increasingly rely on external expertise to implement and maintain their oncology informatics systems. Consulting services play a vital role in helping healthcare organizations select the most suitable solutions and design efficient workflows. Implementation services ensure seamless integration of new systems with existing infrastructure, while training services equip healthcare professionals with the necessary skills to utilize these systems effectively. Maintenance services are critical to ensure the continuous and optimal performance of oncology informatics solutions, th

The CHAIMELEON project aims to set up a pan-European repository of health imaging data, tools and methodologies, with the ambition to set a standard and provide resources for future AI experimentation for cancer management. The project is a 4 year long, EU-funded project tackling some of the most ambitious research in the fields of biomedical imaging, artificial intelligence and cancer treatment, addressing the four types of cancer that currently have the highest prevalence worldwide: lung, breast, prostate and colorectal. To allow this, clinical partners and external collaborators will populate the repository with multimodality (MR, CT, PET/CT) imaging and related clinical data. Subsequently, AI developers will enable a multimodal analytical data engine facilitating the interpretation, extraction and exploitation of the information stored at the repository. The development and implementation of AI-powered pipelines will enable advancement towards automating data deidentification, curation, annotation, integrity securing and image harmonization. By the end of the project, the usability and performance of the repository as a tool fostering AI experimentation will be technically validated, including a validation subphase by world-class European AI developers, participating in Open Challenges to the AI Community. Upon successful validation of the repository, a set of selected AI tools will undergo early in-silico validation in observational clinical studies coordinated by leading experts in the partner hospitals. Tool performance will be assessed, including external independent validation on hallmark clinical decisions in response to some of the currently most important clinical end points in cancer. The project brings together a consortium of 18 European partners including hospitals, universities, R&D centers and private research companies, constituting an ecosystem of infrastructures, biobanks, AI/in-silico experimentation and cloud computing technologies in oncology.

This dataset was used for training and validating the PredictONCO web tool, supporting decision-making in precision oncology by extending the bioinformatics predictions with advanced computing and machine learning. The dataset consists of 1073 single-point mutants of 42 proteins, whose effect was classified as Oncogenic (509 data points) and Benign (564 data points). All mutations were annotated with a clinically verified effect and were compiled from the ClinVar and OncoKB databases. The dataset was manually curated based on the available information in other precision oncology databases (The Clinical Knowledgebase by The Jackson Laboratory, Personalized Cancer Therapy Knowledge Base by MD Anderson Cancer Center, cBioPortal, DoCM database) or in the primary literature. To create the dataset, we also removed any possible overlaps with the data points used in the PredictSNP consensus predictor and its constituents. This was implemented to avoid any test set data leakage due to using the PredictSNP score as one of the features (see below).

The entire dataset (SEQ) was further annotated by the pipeline of PredictONCO. Briefly, the following six features were calculated regardless of the structural information available: essentiality of the mutated residue (yes/no), the conservation of the position (the conservation grade and score), the domain where the mutation is located (cytoplasmic, extracellular, transmembrane, other), the PredictSNP score, and the number of essential residues in the protein. For approximately half of the data (STR: 377 and 76 oncogenic and benign data points, respectively), the structural information was available, and six more features were calculated: FoldX and Rosetta ddg_monomer scores, whether the residue is in the catalytic pocket (identification of residues forming the ligand-binding pocket was obtained from P2Rank), and the pKa changes (the minimum and maximum changes as well as the number of essential residues whose pKa was changed – all values obtained from PROPKA3). For both STR and SEQ datasets, 20% of the data was held out for testing. The data split was implemented at the position level to ensure that no position from the test data subset appears in the training data subset.

For more details about the tool, please visit the help page or get in touch with us.

14-Dec-2023 update: the file with features PredictONCO-features.txt now includes UniProt IDs, transcripts, PDB codes, and mutations.

RATIONALE: A screening questionnaire may help doctors plan better treatment for older patients with cancer. PURPOSE: This clinical trial is studying a questionnaire in screening older patients with cancer.

AI-Enhanced Oncology Prior-Auth Market Outlook

According to our latest research, the AI-Enhanced Oncology Prior-Auth market size reached USD 1.37 billion globally in 2024, reflecting the rapid adoption of artificial intelligence in streamlining oncology prior-authorization processes. The market is projected to grow at a robust CAGR of 18.4% from 2025 to 2033, with the total market value anticipated to reach USD 6.01 billion by 2033. This impressive growth trajectory is driven by the increasing complexity of oncology treatments, the urgent need to reduce administrative burdens, and the demand for faster, error-free authorization workflows in cancer care.

The primary growth factor propelling the AI-Enhanced Oncology Prior-Auth market is the escalating prevalence of cancer worldwide, which places immense pressure on healthcare systems to deliver timely and accurate treatment approvals. Oncology prior-authorization processes are traditionally labor-intensive, prone to human error, and often result in treatment delays that can adversely affect patient outcomes. By leveraging advanced AI algorithms, healthcare providers can automate eligibility checks, documentation, and decision-making, significantly reducing turnaround times and administrative costs. The market is also benefiting from the integration of AI solutions with electronic health records (EHRs), which enhances data accessibility and supports more informed, rapid decision-making for complex oncology cases.

Another critical driver for the AI-Enhanced Oncology Prior-Auth market is the increasing adoption of value-based care models and the corresponding emphasis on operational efficiency. Payers and providers are under mounting pressure to optimize resource allocation while ensuring compliance with regulatory requirements. AI-powered prior-authorization platforms offer sophisticated analytics, predictive modeling, and real-time communication features that streamline interactions between providers, payers, and patients. This not only expedites the approval process but also minimizes denials and appeals, contributing to improved patient satisfaction and financial performance for healthcare organizations. Furthermore, the growing volume of oncology data, including genomic and biomarker information, necessitates advanced AI tools capable of processing and interpreting complex datasets to support precision medicine approaches.

The market’s expansion is further supported by significant investments in healthcare IT infrastructure and favorable government initiatives aimed at modernizing cancer care pathways. Several countries are launching pilot programs and funding opportunities to accelerate the deployment of AI-driven solutions in oncology, recognizing their potential to alleviate administrative bottlenecks and enhance clinical decision support. The proliferation of cloud-based platforms and the rise of telemedicine have also broadened access to AI-enhanced prior-auth tools, particularly in underserved regions. Additionally, collaborations between technology vendors, pharmaceutical companies, and healthcare providers are fostering innovation and enabling the development of tailored AI solutions that address the unique challenges of oncology prior-authorization.

Regionally, North America dominates the AI-Enhanced Oncology Prior-Auth market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. The United States, in particular, is at the forefront due to its advanced healthcare ecosystem, high cancer incidence rates, and proactive adoption of digital health technologies. Europe is witnessing steady growth driven by cross-border healthcare initiatives and increasing investments in AI research. Meanwhile, Asia Pacific is emerging as a lucrative market, propelled by rising healthcare expenditures, expanding cancer screening programs, and the digital transformation of healthcare delivery in countries such as China, Japan, and India. Latin America and the Middle East & Africa are also showing gradual uptake, supported by efforts to strengthen oncology care infrastructure and improve patient access to advanced therapies.

Component Analysis

The AI-Enhanced Oncology Prior-Auth market by component is segmented into Software, Hardware, and Services. Software solutions represent the backbone of this market, encompassing AI-driven platforms that automate prior-authorization workflows, integrate with EHRs, and provide real-t

Oncology EMR Software Market Outlook

The global Oncology EMR Software market size was valued at USD 6.5 billion in 2023 and is projected to reach USD 14.2 billion by 2032, growing at a remarkable CAGR of 9.2% during the forecast period. This impressive growth can be attributed to factors such as the rising prevalence of cancer, the increasing adoption of electronic health records (EHRs), and a growing focus on precision medicine and personalized treatment plans. With technological advancements and increased investment in healthcare IT, the Oncology EMR Software market is set to expand significantly over the next decade.

One of the primary growth factors driving the Oncology EMR Software market is the rising prevalence of cancer worldwide. As cancer cases continue to surge, the need for efficient and comprehensive management of patient data becomes paramount. Oncology EMR software streamlines the documentation process, ensuring that oncologists have quick and easy access to accurate patient information. This enhances clinical decision-making and ultimately leads to better patient outcomes. Additionally, the increasing awareness about early cancer detection and the availability of advanced diagnostic tools contribute to the growing demand for oncology-specific EMR solutions.

Another critical factor contributing to the market's growth is the increasing adoption of electronic health records (EHRs) across the healthcare industry. Governments and healthcare organizations are increasingly recognizing the benefits of digitized patient records, such as improved data accuracy, reduced paperwork, and enhanced coordination of care. Oncology EMR software, being a specialized subset of EHRs, offers features tailored to the unique needs of oncology practices, such as chemotherapy management, radiation therapy tracking, and tumor staging. The integration of these features into a unified platform improves workflow efficiency and supports comprehensive patient care.

The growing focus on precision medicine and personalized treatment plans is also driving the demand for Oncology EMR Software. Precision medicine involves tailoring medical treatment to the individual characteristics of each patient, which requires detailed and accurate patient data. Oncology EMR software facilitates the collection, storage, and analysis of such data, enabling oncologists to develop personalized treatment plans based on genetic, environmental, and lifestyle factors. This approach not only improves treatment efficacy but also minimizes potential side effects, leading to better patient satisfaction and quality of life.

In the realm of specialized medical fields, Dermatology EMR Software has emerged as a crucial tool for dermatologists. This software is designed to cater specifically to the needs of dermatology practices, offering features such as image management, teledermatology capabilities, and integration with dermatoscopes. Dermatology EMR Software streamlines the documentation and management of patient data, allowing dermatologists to efficiently track patient history, treatment plans, and outcomes. The software's ability to handle high-resolution images and support telemedicine consultations is particularly valuable in dermatology, where visual assessments are key. As the demand for dermatology services continues to rise, driven by factors such as increasing skin cancer rates and growing awareness of skin health, the adoption of Dermatology EMR Software is expected to grow, enhancing the quality of care and operational efficiency in dermatology practices.

Regionally, the Oncology EMR Software market is witnessing significant growth across various geographies, with North America leading the market due to the presence of advanced healthcare infrastructure, high adoption rates of EHRs, and substantial government initiatives promoting digital health solutions. Europe and Asia Pacific are also experiencing rapid market growth, driven by increasing cancer prevalence, rising healthcare expenditure, and growing awareness about the benefits of oncology-specific EMR systems. The Middle East & Africa and Latin America regions are gradually adopting these solutions, with efforts to enhance healthcare infrastructure and improve cancer care services.

Component Analysis

The Oncology EMR Software market can be segmented by component into software and services. The software segment comprises various EMR platforms specifically designed for oncology practices, offering features suc

The U.S. AI In Oncology Market size was valued at USD 1.65 billion in 2023 and is projected to reach USD 9.39 billion by 2032, exhibiting a CAGR of 28.2 % during the forecasts period. Artificial Intelligence (AI) in oncology refers to the integration of advanced computational technologies and machine learning algorithms to enhance cancer care and research. AI applications in oncology range from diagnostic tools that improve the accuracy of detecting malignancies to predictive models that assist in prognosis and personalized treatment planning. These technologies analyze vast amounts of medical data, including imaging and genomic information, to identify patterns and insights that may not be immediately apparent to human clinicians. AI systems in oncology are used in various clinical settings, such as radiology, where they help interpret medical images, and pathology, where they assist in analyzing tissue samples. These AI tools can expedite the diagnostic process, increase diagnostic accuracy, and reduce the likelihood of human error. Moreover, AI is being employed in the development of new cancer drugs, utilizing its predictive capabilities to discover novel targets and design drug candidate molecules. Recent developments include: In November 2021, Kheiron Medical Technologies received FDA clearance to introduce its Mia IQ software in the U.S. The software, powered by AI & Machine Learning (ML), is designed to identify potential discrepancies in breast positioning & compression and retrospectively review mammograms , In November 2021, the company integrated TeraRecon as a ConcertAI company, integrating electronic health records, genomic datasets, and medical imaging data into one network of AI-powered workflow. This integration made ConcertAI one of the first unified AI-powered SaaS companies in the U.S. , In June 2021, ConcertAI collaborated with the U.S. FDA to broaden the usage of real-world data in regulatory decision-making. The U.S. FDA would utilize real-world evidence data in assessing the safety of drugs post-approval , In June 2023, iCAD, Inc. signed a strategic multiyear commercial agreement with Radiology Partners, one of the largest radiology practices in the U.S. This will allow iCAD to leverage Radiology Partners’ clinical expertise, AI platform, and scale to expand access to the Company’s Breast AI Suite to millions of patients and their physicians .

Oncology Information System Market Outlook

The global oncology information system market is poised for substantial growth in the coming years, with a market size that was valued at approximately $3.7 billion in 2023. Projected to expand at a compound annual growth rate (CAGR) of 9.8% from 2024 to 2032, the market is expected to reach around $7.8 billion by 2032. This robust growth is primarily driven by the increasing prevalence of cancer worldwide, which necessitates the use of sophisticated information systems to streamline oncology care processes and improve patient outcomes. As the demand for efficient and holistic cancer care management continues to rise, oncology information systems are becoming indispensable tools in the arsenals of healthcare providers.

A significant driver of growth in the oncology information system market is the rising incidence of cancer globally. With cancer remaining one of the leading causes of mortality and morbidity worldwide, there is an urgent need for robust systems that can manage the complexities of oncology treatment, including patient data management, treatment planning, and follow-up care. Advances in medical technology, including precision medicine and personalized treatment plans, have further underscored the need for sophisticated information systems capable of handling vast and varied datasets efficiently. This trend is likely to continue as healthcare providers and systems prioritize the integration of comprehensive data management solutions to improve the accuracy and effectiveness of cancer treatment protocols.

Another crucial factor contributing to the market's expansion is the integration of artificial intelligence (AI) and machine learning (ML) technologies within oncology information systems. AI and ML are transforming the healthcare landscape by providing predictive analytics for early diagnosis and personalized treatment options. These technologies enhance the capabilities of oncology information systems by enabling faster data processing and more precise treatment planning. As a result, the adoption of AI-driven oncology information systems is anticipated to accelerate, driven by the need for improved patient outcomes and the optimization of treatment regimens, ultimately contributing to the market's growth.

The increasing focus on healthcare infrastructure development, particularly in emerging economies, also supports market growth. Governments and healthcare organizations in regions such as Asia Pacific and Latin America are investing heavily in healthcare system advancements, prioritizing the implementation of comprehensive oncology information systems. These investments are aimed at addressing the growing cancer burden and improving healthcare delivery. As countries continue to enhance their healthcare capabilities, the adoption of oncology information systems is expected to rise, further propelling market growth in these regions.

Oncology Automation is increasingly becoming a pivotal component in the evolution of oncology information systems. By automating routine and complex tasks, such as data entry, treatment scheduling, and patient monitoring, oncology automation significantly enhances the efficiency and accuracy of cancer care processes. This technological advancement not only reduces the administrative burden on healthcare professionals but also minimizes the risk of human error, thereby improving patient safety and treatment outcomes. As healthcare providers strive to deliver more efficient and precise oncology care, the integration of automation technologies within information systems is expected to accelerate. This trend is particularly evident in the growing adoption of robotic process automation (RPA) and automated data analytics, which are transforming the way oncology departments operate and manage patient care.

Regionally, North America remains a dominant force in the oncology information system market, largely due to its advanced healthcare infrastructure and significant investments in cancer research and treatment. Europe follows closely, driven by a well-established healthcare system and increasing government initiatives to combat cancer. However, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period, fueled by rapid economic development, increasing healthcare expenditure, and a growing focus on digital health solutions. The Middle East & Africa and Latin America regions are also expected to experience steady growth, supported by improving healthcare infrastructures and rising awareness of the b

OBJECTIVES: Scalable informatics solutions that provide molecularly-tailored treatment recommendations to clinicians are needed to streamline Precision Oncology in care settings. MATERIALS AND METHODS: We developed a cloud-based virtual molecular tumor board (VMTB) platform that included a knowledgebase, scoring model, rules engine, an asynchronous virtual chat room and a reporting tool that generated a treatment plan for each of the 1725 patients based on their molecular profile, previous treatment history, structured trial eligibility criteria, clinically relevant cancer gene-variant assertions, biomarker-treatment associations, and current treatment guidelines. The VMTB systematically allows clinician users to combine expert-curated data and structured data from clinical charts along with molecular testing data to develop consensus on treatments, especially those that require off-label and clinical trial considerations. RESULTS: The VMTB was used as part of the cancer care process for a focused subset of 1725 patients referred by advocacy organizations wherein resultant personalized reports were successfully delivered to treating oncologists. Median turnaround time from data receipt to report delivery decreased from 14 days to 4 days over 4 years while the volume of cases increased nearly twofold each year. Using a novel scoring model for ranking therapy options, oncologists chose to implement the VMTB-derived therapies over others, except when pursuing immunotherapy options without molecular support. DISCUSSION: VMTBs will play an increasingly critical role in precision oncology as the compendium of biomarkers and associated therapy options available to a patient continues to expand. CONCLUSION: Further development of such clinical augmentation tools that systematically combine patient-derived molecular data, real world evidence from electronic health records, and expert curated knowledgebases on biomarkers with computational tools for ranking best treatments can support care pathways at point of care.

In recent decades, there has been a deluge in the large-scale production of anticancer agents, primarily due to advances in genomic technologies enabling precise targeting of oncogenic pathways involved in disease progression. This initiated a paradigm shift in cancer research and therapeutics based on the ability to study molecular changes throughout the genome. It provided a unique opportunity in the field of translational cancer research and have led to the concept of precision medicine in cancer therapy, raising hopes of developing better diagnostic and therapeutic means for the management of cancer. The purpose of this article is to briefly review the tools and techniques involved in precision oncology research and their applications in the field of cancer treatment.

For decades, researchers have used the concepts of rate of change and differential equations to model and forecast neoplastic processes. This expressive mathematical apparatus brought significant insights in oncology by describing the unregulated proliferation and host interactions of cancer cells, as well as their response to treatments. Now, these theories have been given a new life and found new applications. With the advent of routine cancer genome sequencing and the resulting abundance of data, oncology now builds an “arsenal” of new modeling and analysis tools. Models describing the governing physical laws of tumor–host–drug interactions can be now challenged with biological data to make predictions about cancer progression. Our study joins the efforts of the mathematical and computational oncology community by introducing a novel machine learning system for data-driven discovery of mathematical and physical relations in oncology. The system utilizes computational mechanisms such as competition, cooperation, and adaptation in neural networks to simultaneously learn the statistics and the governing relations between multiple clinical data covariates. Targeting an easy adoption in clinical oncology, the solutions of our system reveal human-understandable properties and features hidden in the data. As our experiments demonstrate, our system can describe nonlinear conservation laws in cancer kinetics and growth curves, symmetries in tumor’s phenotypic staging transitions, the preoperative spatial tumor distribution, and up to the nonlinear intracellular and extracellular pharmacokinetics of neoadjuvant therapies. The primary goal of our work is to enhance or improve the mechanistic understanding of cancer dynamics by exploiting heterogeneous clinical data. We demonstrate through multiple instantiations that our system is extracting an accurate human-understandable representation of the underlying dynamics of physical interactions central to typical oncology problems. Our results and evaluation demonstrate that, using simple—yet powerful—computational mechanisms, such a machine learning system can support clinical decision-making. To this end, our system is a representative tool of the field of mathematical and computational oncology and offers a bridge between the data, the modeler, the data scientist, and the practicing clinician.

Using Excel Data Analysis Tools and BigML Machine Learning platform, we tested correlation between biopsy data for breast cancer and created a model which helps to distinguish between benign and malignant tumors. Data set of oncology patients were used to analyze links between 10 indicators collected by biopsy non- cancerous and cancerous tumours. Created model can be used as a future medical science tool and can be available to specially trained histology nurses in rural areas. Developed model that can be used to detect cancer on early stages is especially important in the view of the fact that detecting cancer at stage IV give patients of about 22% of survival rate 1.

The oncology automation market is experiencing robust growth, driven by the increasing prevalence of cancer globally, the rising demand for improved patient care, and the need for enhanced efficiency in oncology practices. The market, estimated at $5 billion in 2025, is projected to witness a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033, reaching approximately $15 billion by 2033. This expansion is fueled by several key factors. Technological advancements in artificial intelligence (AI), robotic process automation (RPA), and database management systems are streamlining various oncology workflows, leading to faster diagnosis, improved treatment planning, and reduced administrative burdens. The integration of electronic medical records (EMR) systems with oncology-specific automation tools further enhances data management and facilitates seamless information sharing among healthcare providers. The adoption of automation is particularly strong among oncologists, pharmacists, and technicians, owing to the complexity and data-intensive nature of their tasks. However, high initial investment costs, concerns about data security and privacy, and the need for skilled personnel to implement and manage these systems pose challenges to wider market penetration. Nevertheless, the long-term benefits of improved accuracy, efficiency, and patient outcomes are expected to outweigh these restraints, driving continued market expansion. Market segmentation reveals a significant share held by AI-powered solutions, reflecting the growing importance of data analytics and predictive modeling in oncology. Robotic process automation is also gaining traction, automating repetitive tasks and freeing up healthcare professionals to focus on patient care. The North American market currently dominates, owing to advanced healthcare infrastructure and higher adoption rates of innovative technologies. However, significant growth potential exists in other regions, particularly in Asia Pacific, driven by rising healthcare expenditure and increasing cancer incidence rates. Leading companies are actively investing in research and development to expand their product offerings and enhance their market presence. The competitive landscape is dynamic, with both established players and emerging companies vying for market share through strategic partnerships, acquisitions, and product innovations. This ongoing evolution promises further technological advancement and increased affordability, making oncology automation more accessible to a wider range of healthcare facilities worldwide.

Leo and colleagues used multi-omic analysis for studies of childhood Acute lymphoblastic leukemia (ALL) . New tool for improving childhood ALL cancer treatment developed and shared.